Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00126412|
Recruitment Status : Completed
First Posted : August 4, 2005
Last Update Posted : May 16, 2007
|Condition or disease||Intervention/treatment||Phase|
|Pheochromocytoma Neuroblastoma||Drug: 123I-mIBG (meta-iodobenzylguanidine)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||185 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||July 2005|
- - To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.
- To determine the incremental value of single-photon emission computed tomography (SPECT) for improving the sensitivity and specificity of 123I-mIBG planar scintigraphy for the diagnoses of neuroblastoma and phaeochromocytoma.
- To collect safety data on 123I-mIBG.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00126412
|United States, New Jersey|
|Princeton, New Jersey, United States, 08540|
|Study Director:||Diane McCaul||GE Healthcare|